Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
| العنوان: | Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma |
|---|---|
| المؤلفون: | Paola Andreani, René Adam, Catherine Guettier, Daniel Azoulay, Marie-Pierre Bralet, Bernard Paule, Denis Castaing |
| المصدر: | Clinical Medicine. Oncology Clinical Medicine Insights: Oncology, Vol 3 (2009) |
| بيانات النشر: | Libertas Academica, 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | medicine.medical_specialty, Pathology, medicine.medical_treatment, GemOx, liver, Gastroenterology, lcsh:RC254-282, Internal medicine, Medicine, Recurrent Cholangiocarcinoma, Survival rate, Original Research, Chemotherapy, Cetuximab, business.industry, oxaliplatin, gemcitabine, Cancer, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Gemcitabine, Oxaliplatin, adjuvant chemotherapy, Oncology, business, cholangiocarcinoma, epidermal growth factor receptor, medicine.drug |
| الوصف: | Background There is no standard adjuvant chemotherapy to prevent recurrent cholangiocarcinoma (CCA), a rare cancer with poor prognosis. We assessed the efficacy and safety of GEMOX on intrahepatic and hilar CCA with high-risk factors after curative surgery. Patients and Methods Twenty two patients (mean age: 57 years old) with CCA received 6 cycles of GEMOX: gemcitabine 1,000 mg/m2 on day 1 and oxaliplatin 85 mg/m2 on day 2, q3w after a curative surgery. Results All patients completed 6 cycles of GEMOX. EGFR membranous expression was present in 20 CCA. The 5-year survival rate was 56% (CI 95%: 25.7–85.4); 2-year disease free survival rate was 28% (CI 95%: 3.4–52.6). Median time to progression was 15 months. The rate of recurrence after surgery and chemotherapy was 63% (14/22). Two patients died of disease progression. Twelve patients received cetuximab/GEMOX at the time of relapse. Six died after 12 months (9–48 months), three are still alive suggesting a clinical applicability of EGFR inhibitors in CCA. Conclusion Adjuvant chemotherapy with GEMOX alone seems ineffective in intrahepatic and hilar CCA with a high risk of relapse. Additional studies including targeted therapies to circumvent such poor chemosensitivity are needed. |
| اللغة: | English |
| تدمد: | 1177-9314 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::429659ec93ab447af829c498480aab75Test http://europepmc.org/articles/PMC2872598Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....429659ec93ab447af829c498480aab75 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 11779314 |
|---|